Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given written consent to participate voluntarily
- People aged 18 years or older
- People who have been newly diagnosed with acute myeloid leukaemia (AML) and have been assessed as not suitable for intensive chemotherapy, either because they are 75 or older, or because they are aged 18 to 74 and have at least one of the following health conditions: a low activity or functioning level (as rated by their doctor), heart failure requiring treatment or reduced heart pumping function or stable chest pain (angina), reduced lung function based on breathing tests, reduced kidney function within a certain range, moderate liver impairment, or another condition their doctor considers incompatible with intensive chemotherapy
- People who are medically suitable for intensive chemotherapy but have chosen not to receive it
- People whose liver function test results fall within the levels specified by the trial (confirm with trial site)
- People whose kidney function shows a creatinine clearance of at least 30 mL/min, measured using a standard formula
- People with a life expectancy of at least 4 weeks
Who may not be able to join:
- People who have a history of other cancers before entering the study (some exceptions may apply — confirm with trial site)
- People with a known HIV infection, or active hepatitis B or hepatitis C infection
- People whose AML has spread to the central nervous system (the brain and spinal cord)
- People who have already received treatment for AML, except for a medication called hydroxyurea
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 18017337037
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants With Composite Complete Remission
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.